Trial site
Centre Hospitalier Intercommunal De Poissy Saint Germain
Poissy, 78300, FranceNot linked to an institution yet
- 17running trials
- 6closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 319 trials
- Phase 43 trials
- Phase 21 trial
- Status
- Recruiting10 trials
- Completed6 trials
- Active, not recruiting5 trials
- Not yet recruiting2 trials
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris5 trials
- Hoffmann-La Roche3 trials
- Novartis Pharmaceuticals3 trials
- Zenas BioPharma (USA), LLC2 trials
- Assistance Publique Hopitaux De Paris1 trial
- and 9 more
Running trials
Not yet recruiting
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source
Not yet recruiting
Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial
2025-524976-40-00· Phase 3· Centre Hospital Region Metz Thionville· Source
Recruiting
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
NCT07189325· Phase 3· University Hospital, Montpellier· Source
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source
Recruiting
Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression
NCT06833788· Phase 4· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
NCT06675955· Phase 3· Hoffmann-La Roche· Source
Recruiting
For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial
2023-505420-62-00· Phase 3· Hopital Fondation Adolphe De Rothschild· Source
Recruiting
Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology.
2022-500933-10-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Recruiting
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
NCT05758831· Phase 3· Rennes University Hospital· Source
Recruiting
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
NCT05476991· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX).
NCT04968899· Phase 3· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
NCT04751877· Phase 3· Poitiers University Hospital· Source
Recruiting
Short Treatment with Omalizumab for Severe Asthma
NCT04763447· Phase 4· Assistance Publique - Hôpitaux de Paris· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error